SG11201610073PA - Peptides as oxytocin agonists - Google Patents

Peptides as oxytocin agonists

Info

Publication number
SG11201610073PA
SG11201610073PA SG11201610073PA SG11201610073PA SG11201610073PA SG 11201610073P A SG11201610073P A SG 11201610073PA SG 11201610073P A SG11201610073P A SG 11201610073PA SG 11201610073P A SG11201610073P A SG 11201610073PA SG 11201610073P A SG11201610073P A SG 11201610073PA
Authority
SG
Singapore
Prior art keywords
peptides
oxytocin agonists
oxytocin
agonists
Prior art date
Application number
SG11201610073PA
Other languages
English (en)
Inventor
Caterina Bissantz
Konrad Bleicher
Christophe Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50842169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201610073P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201610073PA publication Critical patent/SG11201610073PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201610073PA 2014-06-03 2015-06-01 Peptides as oxytocin agonists SG11201610073PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170992 2014-06-03
PCT/EP2015/062054 WO2015185467A1 (en) 2014-06-03 2015-06-01 Peptides as oxytocin agonists

Publications (1)

Publication Number Publication Date
SG11201610073PA true SG11201610073PA (en) 2016-12-29

Family

ID=50842169

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610073PA SG11201610073PA (en) 2014-06-03 2015-06-01 Peptides as oxytocin agonists

Country Status (16)

Country Link
US (1) US9957298B2 (ru)
EP (1) EP3151849B1 (ru)
JP (1) JP6412170B2 (ru)
KR (1) KR20170004013A (ru)
CN (1) CN106414479B (ru)
AU (1) AU2015270723A1 (ru)
CA (1) CA2949173A1 (ru)
CL (1) CL2016003095A1 (ru)
CR (1) CR20160563A (ru)
EA (1) EA030091B1 (ru)
IL (1) IL248553A0 (ru)
MX (1) MX2016015873A (ru)
PE (1) PE20161559A1 (ru)
PH (1) PH12016502232A1 (ru)
SG (1) SG11201610073PA (ru)
WO (1) WO2015185467A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044131A1 (en) 2014-09-19 2016-03-24 Ferring B.V. Method of treating prader-willi syndrome
US11414459B2 (en) 2017-09-28 2022-08-16 Kinoxis Therapeutics Pty Ltd Metabolite inspired selective oxytocin receptor agonists
KR20210062638A (ko) * 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신의 안정한 비강내 제형
WO2020061416A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
KR20070022753A (ko) * 2004-05-26 2007-02-27 화이자 인코포레이티드 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
MX2009007831A (es) * 2007-01-22 2010-01-15 Gtx Inc Agentes de union de receptor nuclear.
CN101983205B (zh) * 2008-03-31 2015-08-19 辉凌公司 催产素类似物
JP2012502948A (ja) * 2008-09-23 2012-02-02 エフ．ホフマン−ラ ロシュ アーゲー ドーパミンｄ３受容体の調節剤として有用なイソオキサゾロ［４，５］ピリジン−３−イル−ピペラジン誘導体
SG175780A1 (en) * 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyridazine derivatives
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
WO2011038451A1 (en) * 2009-10-01 2011-04-07 The University Of Sydney Therapy and prevention of problem drinking
JP6067878B2 (ja) 2012-12-21 2017-01-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オキシトシンアゴニストとしてのペプチド

Also Published As

Publication number Publication date
IL248553A0 (en) 2016-12-29
US9957298B2 (en) 2018-05-01
EA201692404A1 (ru) 2017-05-31
KR20170004013A (ko) 2017-01-10
EP3151849B1 (en) 2018-10-10
US20170081369A1 (en) 2017-03-23
PH12016502232A1 (en) 2017-01-09
PE20161559A1 (es) 2017-01-12
CA2949173A1 (en) 2015-12-10
EP3151849A1 (en) 2017-04-12
WO2015185467A1 (en) 2015-12-10
MX2016015873A (es) 2017-03-27
CR20160563A (es) 2017-01-06
JP2017518311A (ja) 2017-07-06
EA030091B1 (ru) 2018-06-29
CN106414479B (zh) 2021-08-03
CN106414479A (zh) 2017-02-15
JP6412170B2 (ja) 2018-10-24
CL2016003095A1 (es) 2017-06-16
AU2015270723A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
GB201418562D0 (en) Peptides
IL248625A0 (en) Peptides as oxytocin agonists
GB201508337D0 (en) Novel peptides
HK1243106A1 (zh) 唾液富酪蛋白肽
GB201520546D0 (en) Peptides
GB201520536D0 (en) Peptides
IL248553A0 (en) Peptides as oxytocin agonists
GB201401877D0 (en) Peptides
GB201520545D0 (en) Peptides
GB201520544D0 (en) Peptides
GB201520541D0 (en) Peptides
GB201520539D0 (en) Peptides
GB201520543D0 (en) Peptides
HK1253316A1 (zh) 肽
GB201503483D0 (en) Novel Antimmicrobial Peptides
GB201520542D0 (en) Peptides
GB201409536D0 (en) Chemically modifying peptides
GB201420645D0 (en) Peptides
GB201408629D0 (en) Novel peptides
GB201412731D0 (en) Peptides
GB201520535D0 (en) Peptides
GB201520547D0 (en) Peptides
GB201520534D0 (en) Peptides
GB201520537D0 (en) Peptides
GB201520538D0 (en) Peptides